Source-grounded facts extracted from PSYCHEMEDICS CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
PSYCHEMEDICS CORP reported the first quarter ended March 31, 2024 results: revenue $5.4 million, net income $0.7 million, EPS $0.12 per share.
“The Company’s revenue for the quarter ended March 31, 2024, was $5.4 million versus $5.9 million for the quarter ended March 31, 2023, a decrease of 9%. Net loss for the quarter was $0.7 million, or $0.12 per share, compared to a net loss of $0.4 million, or $.07 per share, for the comparable quarter last year.”
PSYCHEMEDICS CORP reported the year ended December 31, 2023 results: revenue $22.1 million, net income net loss of approximately $4.2 million, EPS $0.72 per share.
“but also solidify our position as the leader in the industry,” added Shannon Shoemaker, Chief Revenue Officer. The Company's revenue for the year ended December 31, 2023, was $22.1 million versus $25.2 million for the prior year, a decrease of 12%. As of December 31, 2023, the Company had cash and cash equivalents of approximately $2.0 million, compared with”
Daniella Mehalik was appointed as Vice President – Finance and Treasurer at PSYCHEMEDICS CORP.
“On November 27, 2023, the Psychemedics Corporation (the “Company”) appointed Daniella Mehalik as Vice President – Finance and as Treasurer of the Company.”
PSYCHEMEDICS CORP reported the third quarter ended September 30, 2023 results: revenue $5.7 million, net income $(2.1 million), EPS $(0.36) per diluted share.
“The Company’s revenue for the quarter ended September 30, 2023, was $5.7 million versus $6.5 million for the quarter ended September 30, 2022, a decrease of 12%. Net loss for the quarter ended September 30, 2023, was $(2.1 million) or $(0.36) per diluted share, versus net loss of $(97,000) or $(0.02) per diluted share, for the comparable period last year.”
Michael Schaffer departed as Vice President of Laboratory Operations at PSYCHEMEDICS CORP.
“Effective November 3, 2023, Michael Schaffer ceased serving as Vice President of Laboratory Operations of Psychemedics Corporation (the "Company") and is no longer employed by the Company.”
Michael Weisenhoff resigned as Assistant Controller at PSYCHEMEDICS CORP.
“On September 20, 2023, Michael Weisenhoff, Assistant Controller, resigned from such position effective September 29, 2023, to take a position with another company.”
Charles Doucot departed as Executive Vice President at PSYCHEMEDICS CORP.
“Charles Doucot, the Company’s Executive Vice President, will be leaving the Company effective September 15, 2023.”
PSYCHEMEDICS CORP shareholders approved Ratification of appointment of BDO USA, P.A. as independent registered public accounting firm at the 2023-12-31 meeting.
“Proposal No. 3. Ratification of Appointment of Independent Registered Public Accounting Firm. The stockholders ratified the appointment of BDO USA, P.A. as the Company's independent registered public accounting firm for the year ending December 31, 2023, by the votes set forth in the table below: For Against Abstain Broker Non-Votes 4,223,842 36,638 7,850 0”
PSYCHEMEDICS CORP shareholders approved Advisory vote on executive compensation.
“Proposal No. 2. Advisory Vote on Executive Compensation. The stockholders approved a non-binding advisory resolution to approve executive compensation, as described in the Proxy Statement, by the votes set forth in the table below: For Against Abstain Broker Non-Votes 2,855,077 170,531 13,981 1,228,741”
PSYCHEMEDICS CORP shareholders approved Election of six directors to serve until the 2024 Annual Meeting.
“Proposal No. 1. Election of Directors. The stockholders elected six directors to serve until the Company's 2024 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, by the votes set forth in the table below: Nominees For Withheld Broker Non-Votes Robyn C. Davis 2,898,919 140,670 1,228,741 Brian Hullinger 2,996,505 43,084 1,228,741 Peter H. Kamin 2,974,032 65,557 1,228,741 Darius G. Nevin 2,938,911 100,678 1,228,741 Andrew M. Reynolds 2,805,910 233,679 1,228,741”
PSYCHEMEDICS CORP reported second quarter ended June 30, 2023 results: revenue $5.5 million, net income $(726,000) or $(0.13) per diluted share, EPS $(0.13) per diluted share.
“The Company’s revenue for the quarter ended June 30, 2023, was $5.5 million versus $6.5 million for the quarter ended June 30, 2022, a decrease of 15%. Net loss for the quarter ended June 30, 2023, was $(726,000) or $(0.13) per diluted share, versus net loss of $(338,000) or $(0.06) per diluted share, for the comparable period last year.”
PSYCHEMEDICS CORP entered into Confidential Settlement Agreement and Release with Transportation Insight LLC valued at $500,000.00 (effective 2023-07-17).
“On July 17, 2023, Psychemedics Corporation (the “Company”) entered into a Confidential Settlement Agreement and Release (“Agreement”) with Transportation Insight LLC, a consultant of the Company, to settle a lawsuit against it related to a contract dispute.”
Michael Weisenhoff was appointed as principal financial and accounting manager at PSYCHEMEDICS CORP.
“On July 13, 2023, the Company appointed Michael Weisenhoff, Assistant Controller of the Company, as the Company’s principal financial and accounting manager, to take effect as of July 20, 2023.”
Brian Hullinger was appointed as director at PSYCHEMEDICS CORP.
“He has also been nominated to be elected as a director of the Company at the Annual Meeting of Stockholders to be held on August 17, 2023.”
Brian Hullinger was appointed as President and Chief Executive Officer at PSYCHEMEDICS CORP.
“On July 12, 2023, the Company announced Brian Hullinger as the new President and Chief Executive Officer of the Company, to take effect on August 17, 2023.”
William Norris resigned as Controller at PSYCHEMEDICS CORP.
“On July 12, 2023, William Norris, the Company’s Controller, resigned from such position, and otherwise as an officer of the Company, effective July 21, 2023 to take a position with a home healthcare technology company.”
Fred J. Weinert retired as director at PSYCHEMEDICS CORP.
“On July 12, 2023, Fred J. Weinert, a director of the Company, notified the Company that he will retire as a director effective August 17, 2023 coincident with the Annual Meeting of Stockholders on such date.”
Raymond C. Kubacki retired as Chairman, Chief Executive Officer and President at PSYCHEMEDICS CORP.
“On July 12, 2023 Raymond C. Kubacki, the Company’s Chairman, Chief Executive Officer and President notified the Company that he will retire as Chairman Chief Executive Officer and President effective August 17, 2023 coincident with the Annual Meeting of Stockholders on such date.”
PSYCHEMEDICS CORP reported the first quarter ended March 31, 2023 results: revenue $5.9 million, net income $(384,000), EPS $(0.07) per diluted share.
“The Company’s revenue for the quarter ended March 31, 2023, was $5.9 million versus $6.5 million for the quarter ended March 31, 2022, a decrease of 10%. Net loss for the quarter ended March 31, 2023, was $(384,000) or $(0.07) per diluted share, versus net income of $39,000 or $0.01 per diluted share, for the comparable period last year.”
PSYCHEMEDICS CORP reported the quarter ended December 31, 2022 results: revenue $5.7 million, net income $0.7 million, EPS ($0.12) per diluted share.
“The Company’s revenue for the quarter ended December 31, 2022, was $5.7 million versus $6.4 million for the quarter ended December 31, 2021, a decrease of 11%. Net loss for the quarter ended December 31, 2022, was $0.7 million or ($0.12) per diluted share, versus net loss of $1.6 million or ($0.29) per diluted share, for the comparable period last year.”
PSYCHEMEDICS CORP reported the year ended December 31, 2022 results: revenue $25.2 million, net income $1.1 million, EPS ($0.19) per diluted share.
“The Company's revenue for the year ended December 31, 2022, was $25.2 million versus $24.9 million for the year ended December 31, 2021, an increase of 1%. Net loss for the year ended December 31, 2022, was $1.1 million or ($0.19) per diluted share, versus net loss of $0.7 million or ($0.12) per diluted share, for the comparable period last year.”
William Norris was appointed as Controller at PSYCHEMEDICS CORP.
“On December 30, 2022, the Psychemedics Corporation (the “Company”) appointed William Norris as Controller of the Company, to take effect as of January 1, 2023.”
PSYCHEMEDICS CORP reported the nine months ended September 30, 2022 results: revenue $19.5 million, net income $0.4 million, EPS ($0.07) per diluted share.
“The Company’s revenue for the nine months ended September 30, 2022, was $19.5 million versus $18.5 million for the comparable period in 2021, an increase of 5%. Net loss for the nine months ended September 30, 2022, was $0.4 million or ($0.07) per diluted share, versus net income of $1.0 million or $0.17 per diluted share, for the comparable period last year.”
PSYCHEMEDICS CORP reported the third quarter ended September 30, 2022 results: revenue $6.5 million, net income $0.1 million, EPS ($0.02) per diluted share.
“The Company’s revenue for the quarter ended September 30, 2022, was $6.5 million versus $6.7 million for the quarter ended September 30, 2021, a decrease of 3%. Net loss for the quarter ended September 30, 2022, was $0.1 million or ($0.02) per diluted share, versus net income of $0.7 million or $0.13 per diluted share, for the comparable quarter last year.”
Andrew Limbek resigned as Vice President – Controller at PSYCHEMEDICS CORP.
“On July 19, 2022, Andrew Limbek, the Corporation’s Vice President – Controller, resigned from such position, and otherwise as an officer of the Corporation, to take effect as of the close of business on August 12, 2022, in order to pursue an opportunity with an international accounting firm.”
Walter S. Tomenson, Jr. departed as Director at PSYCHEMEDICS CORP.
“On June 9, 2022, Walter S. Tomenson, Jr., a director of the Board notified the Company that he will be retiring from the Board at the 2022 Annual Meeting.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.